AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31253572 — intervention group
Group type: EXPERIMENTAL
Intervention: IPH4102 (monoclonal antibody targeting KIR3DL2) administered as an intravenous infusion at a flat dose of 750 mg during cohort-expansion.
Number of subjects: 44
Study 31253596 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 232 monotherapy (arm 1) at doses of 60, 120, 240, 360, 480, or 960 mg
Number of subjects: 36
Study 31253596 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 232 at 60 mg with trametinib 2 mg (arm 2)
Number of subjects: 36
Study 31253596 — intervention group
Group type: EXPERIMENTAL
Intervention: Common treatment-related AEs for AMG 232
Number of subjects: 36
Study 31253596 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetics of AMG 232
Number of subjects: 36
Study 31253622 — intervention group
Group type: EXPERIMENTAL
Intervention: All-site screening for CT/NG infections
Number of subjects: 1610
Study 31253622 — intervention group
Group type: COMPARATOR
Intervention: Pharyngeal screening
Number of subjects: 1610
Study 31253622 — intervention group
Group type: COMPARATOR
Intervention: Rectal screening
Number of subjects: 1610
Study 31253622 — intervention group
Group type: COMPARATOR
Intervention: Urethral screening
Number of subjects: 1610
Study 31253623 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants in the HELMi cohort receiving various environmental, lifestyle, and genetic factors assessments through faecal samples and questionnaires.
Number of subjects: 1055
Study 31253623 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor and cognitive developmental screening at 18 months.
Number of subjects: 1055
Study 31253624 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiresistant bacteria (MRB) carriage
Number of subjects: 5117
Study 31253624 — intervention group
Group type: EXPERIMENTAL
Intervention: CPE
Number of subjects: 5117
Study 31253624 — intervention group
Group type: EXPERIMENTAL
Intervention: MRSA
Number of subjects: 5117
Study 31253624 — intervention group
Group type: EXPERIMENTAL
Intervention: VRE
Number of subjects: 5117
Study 31253624 — intervention group
Group type: EXPERIMENTAL
Intervention: ESBL
Number of subjects: 5117
Study 31253727 — intervention group
Group type: EXPERIMENTAL
Intervention: ART+Peg-IFN-α2a after 5 weeks
Number of subjects: 0
Study 31253727 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg-IFN-α2a monotherapy after 12 weeks
Number of subjects: 0
Study 31253727 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg-IFN-α2a immunotherapy
Number of subjects: 0
Study 31253732 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported questionnaires including the Hospital Anxiety and Depression Scale, the Functional Assessment of Cancer Therapy (FACT), General and Brain (FACT-Br), and the Leisure Time Physical Activity Questionnaire.
Number of subjects: 0
Study 31253732 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interviews with patients and caregivers.
Number of subjects: 0
Study 31253732 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance care planning discussions.
Number of subjects: 0
Study 31254057 — intervention group
Group type: EXPERIMENTAL
Intervention: WTC workers with lower airway disease
Number of subjects: 207
Study 31254057 — intervention group
Group type: COMPARATOR
Intervention: COPDGene® WTC-unexposed and asymptomatic subjects
Number of subjects: 207
Study 31254174 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 103101
Study 31254174 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 103101
Study 31254223 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 0
Study 31254223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31254273 — intervention group
Group type: EXPERIMENTAL
Intervention: Plazomicin-based combination therapy (with adjunctive tigecycline or meropenem)
Number of subjects: 15
Study 31254273 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline
Number of subjects: 15
Study 31254273 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 15
Study 31254273 — intervention group
Group type: COMPARATOR
Intervention: Control group (Colistin-based combination therapy)
Number of subjects: 15
Study 31254392 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir (G/P) 300 mg/120 mg once daily for 8-16 weeks
Number of subjects: 48
Study 31254392 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir (G/P)
Number of subjects: 48
Study 31255290 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop vasopressor (CLV) control with norepinephrine infusion
Number of subjects: 20
Study 31255472 — intervention group
Group type: EXPERIMENTAL
Intervention: Cook Zenith p-Branch stent graft
Number of subjects: 30
Study 31255562 — intervention group
Group type: EXPERIMENTAL
Intervention: PASCAL Transcatheter Valve Repair System
Number of subjects: 62
Study 31255638 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot Function Index (FFI)
Number of subjects: 26
Study 31255846 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical storm (ES) in LVAD patients
Number of subjects: 652
Study 31255846 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients experiencing ES
Number of subjects: 652
Study 31255895 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Angiography (CAG)
Number of subjects: 10266
Study 31255895 — intervention group
Group type: EXPERIMENTAL
Intervention: Index Revascularization
Number of subjects: 10266
Study 31255895 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgent Revascularization for very-high-risk patients
Number of subjects: 10266
Study 31255895 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Revascularization for high-risk patients
Number of subjects: 10266
Study 31255895 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital Major Adverse Cardio-Cerebral Events (MACCE)
Number of subjects: 10266
Study 31255895 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of Stay (LOS)
Number of subjects: 10266
Study 31255969 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week weight loss period (≥8% of body weight)
Number of subjects: 24
Study 31255969 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight maintenance period with medium to high dietary protein
Number of subjects: 24
Study 31255969 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline measurement
Number of subjects: 24
Study 31256001 — intervention group
Group type: EXPERIMENTAL
Intervention: Current treatments for anxiety (psychological and pharmacological)
Number of subjects: 0
Study 31256001 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural circuitry modulation by current treatments
Number of subjects: 0
Study 31256022 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral pattern (chronic HBV or HCV)
Number of subjects: 1004
Study 31256022 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic pattern (≥2 metabolic, no lifestyle or viral)
Number of subjects: 1004
Study 31256022 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle pattern (current smoker or alcohol user, no viral)
Number of subjects: 1004
Study 31256022 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral+metabolic risk factors
Number of subjects: 1004
Study 31256022 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle+viral risk factors
Number of subjects: 1004
Study 31256022 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle+metabolic risk factors but not viral
Number of subjects: 1004
Study 31256026 — intervention group
Group type: EXPERIMENTAL
Intervention: Secure prescription pads for zolpidem
Number of subjects: 0
Study 31256026 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidemiological study of the French National Health Insurance database
Number of subjects: 0
Study 31256026 — intervention group
Group type: EXPERIMENTAL
Intervention: Field studies of prescribers and consumers of zolpidem
Number of subjects: 0
Study 31256030 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal imaging and image review by an ophthalmic grader
Number of subjects: 0
Study 31256030 — intervention group
Group type: COMPARATOR
Intervention: Current standard of care (evaluation of patients in clinic by an ophthalmologist)
Number of subjects: 0
Study 31256258 — intervention group
Group type: EXPERIMENTAL
Intervention: First-trimester Perceived Stress Scale (PSS) scores
Number of subjects: 4161
Study 31256258 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-trimester Perceived Stress Scale (PSS) scores
Number of subjects: 4161
Study 31256258 — intervention group
Group type: EXPERIMENTAL
Intervention: PSS scores 2-7 years after delivery
Number of subjects: 4161
Study 31256258 — intervention group
Group type: EXPERIMENTAL
Intervention: First-trimester PSS and PSS increase through pregnancy
Number of subjects: 4161
Study 31256258 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of APOs (HDP, PE, miPTB)
Number of subjects: 4161
Study 31256293 — intervention group
Group type: EXPERIMENTAL
Intervention: Overcontrol in Youth Checklist (OCYC)
Number of subjects: 0
Study 31256774 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative multimodal analgesic regimen
Number of subjects: 1212
Study 31256778 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track protocols in THA/TKA
Number of subjects: 36608
Study 31256779 — intervention group
Group type: EXPERIMENTAL
Intervention: taTME
Number of subjects: 40
Study 31256779 — intervention group
Group type: COMPARATOR
Intervention: CLS
Number of subjects: 40
Study 31256779 — intervention group
Group type: COMPARATOR
Intervention: SPLS
Number of subjects: 40
Study 31257724 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab (1000 mg) plus IVIG
Number of subjects: 25
Study 31258695 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 45
Study 31258922 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker identification for disease progression
Number of subjects: 200
Study 31258922 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood samples, lung function tests, quality of life questionnaires, bronchoscopy (subgroup)
Number of subjects: 200
Study 31258922 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded home handheld spirometry
Number of subjects: 200
Study 31258922 — intervention group
Group type: COMPARATOR
Intervention: Idiopathic pulmonary fibrosis (as positive control)
Number of subjects: 200
Study 31259266 — intervention group
Group type: EXPERIMENTAL
Intervention: NOAC
Number of subjects: 4000
Study 31259266 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonists
Number of subjects: 4000
Study 31259266 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulant
Number of subjects: 4000
Study 31259847 — intervention group
Group type: EXPERIMENTAL
Intervention: University of Pennsylvania Smell Identification Test
Number of subjects: 51
Study 31259847 — intervention group
Group type: EXPERIMENTAL
Intervention: Smell Threshold Test
Number of subjects: 51
Study 31260802 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 42
Study 31260835 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2879552 (0.25 mg-3 mg once daily and 3-mg or 4-mg intermittent dosing)
Number of subjects: 29
Study 31260835 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2879552
Number of subjects: 29
Study 31261514 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib plus docetaxel (docetaxel 75 mg/m² i.v. on day 1 plus oral apatinib 250 mg/day)
Number of subjects: 14
Study 31261514 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib plus docetaxel
Number of subjects: 14
Study 31262301 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year intensive lifestyle intervention (ILI) program
Number of subjects: 180
Study 31262320 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-to-target pointing task in a virtual environment using a haptic stylus
Number of subjects: 64
Study 31262327 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteomic analysis of plasma from patients with AIS due to LVO
Number of subjects: 40
Study 31262327 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-protein panel (PPBP, THBS1, LYVE1, IGF2)
Number of subjects: 40
Study 31262327 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF2, LYVE1, THBS1
Number of subjects: 40
Study 31262327 — intervention group
Group type: EXPERIMENTAL
Intervention: Western blots analysis
Number of subjects: 40
Study 31262337 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid plaque burden and size of plaque compositions (including LRNC and IPH)
Number of subjects: 687
Study 31262337 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume of LRNC
Number of subjects: 687
Study 31262337 — intervention group
Group type: EXPERIMENTAL
Intervention: %LRNC volume
Number of subjects: 687
Study 31262337 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume of IPH
Number of subjects: 687
Study 31262337 — intervention group
Group type: EXPERIMENTAL
Intervention: %IPH volume
Number of subjects: 687
Study 31262337 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume of IPH adjusted for plaque volume
Number of subjects: 687
Study 31262337 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume of IPH adjusted for plaque volume and volume of LRNC
Number of subjects: 687
Study 31262378 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31262581 — intervention group
Group type: EXPERIMENTAL
Intervention: 13 mm needle
Number of subjects: 65
Study 31262581 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mm needle
Number of subjects: 65
Study 31262585 — intervention group
Group type: EXPERIMENTAL
Intervention: Hecolin® vaccine (3 doses at day 0, month 1, month 6)
Number of subjects: 601
Study 31262585 — intervention group
Group type: COMPARATOR
Intervention: Safety control group (no intervention)
Number of subjects: 601
Study 31262783 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19-specific chimeric antigen receptor (CAR) T cells administered following high-dose chemotherapy and autologous stem cell transplantation (HDT-ASCT) on days +2 and +3.
Number of subjects: 15
Study 31263030 — intervention group
Group type: EXPERIMENTAL
Intervention: CRS-207
Number of subjects: 35
Study 31263406 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ASN electrical stimulation (10 Hz)
Number of subjects: 15
Study 31263406 — intervention group
Group type: COMPARATOR
Intervention: Sham ASN electrical stimulation
Number of subjects: 15
Study 31263598 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentry bioconvertible IVC filter
Number of subjects: 129
Study 31263700 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetarian dietary patterns
Number of subjects: 0
Study 31263700 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 31263727 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA) injection
Number of subjects: 86
Study 31263727 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 86
Study 31263960 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily physical activity assessed in steps/day using an arm-worn accelerometer (SenseWear) over 1 week.
Number of subjects: 39
Study 31263960 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walking distance (6MWD) as an independent predictor of daily steps.
Number of subjects: 39
Study 31263960 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of daily physical activity with hemodynamics and other outcomes.
Number of subjects: 39
Study 31264073 — intervention group
Group type: EXPERIMENTAL
Intervention: Trisodium citrate 4%
Number of subjects: 396
Study 31264073 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 396
Study 31264178 — intervention group
Group type: EXPERIMENTAL
Intervention: Edmonton Obesity Staging System (EOSS)
Number of subjects: 9437
Study 31264178 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve Gastrectomy (SG)
Number of subjects: 9437
Study 31264178 — intervention group
Group type: EXPERIMENTAL
Intervention: One-Anastomosis Gastric Bypass (OAGB)
Number of subjects: 9437
Study 31264178 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en Y Gastric Bypass (RYGB)
Number of subjects: 9437
Study 31264386 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung diffusing capacity for nitric oxide (DLNO) measurement
Number of subjects: 0
Study 31264386 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung diffusing capacity for carbon monoxide (DLCO) measurement
Number of subjects: 0
Study 31264693 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) over right posterior superior temporal sulcus (rpSTS)
Number of subjects: 0
Study 31264693 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) over right occipital face area (rOFA)
Number of subjects: 0
Study 31264693 — intervention group
Group type: COMPARATOR
Intervention: Bilateral fusiform face area (FFA) and right occipital face area (rOFA)
Number of subjects: 0
Study 31264693 — intervention group
Group type: COMPARATOR
Intervention: Bilateral human motion-selective area MT+
Number of subjects: 0
Study 31264693 — intervention group
Group type: COMPARATOR
Intervention: Bilateral posterior superior temporal sulcus (pSTS)
Number of subjects: 0
Study 31264957 — intervention group
Group type: EXPERIMENTAL
Intervention: Seegene RV15 multiplex PCR
Number of subjects: 0
Study 31265120 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 18
Study 31265819 — intervention group
Group type: EXPERIMENTAL
Intervention: Through-the-scope (TTS) stent placement
Number of subjects: 32
Study 31265917 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic artery ligation and extrahepatic collaterals division (HALED)
Number of subjects: 19
Study 31266056 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus MR4
Number of subjects: 0
Study 31266056 — intervention group
Group type: COMPARATOR
Intervention: Ciclosporin and Tacrolimus
Number of subjects: 0
Study 31266223 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable EEG-based brain monitoring and seizure prediction system
Number of subjects: 15
Study 31266741 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) recombinant human IL-15 (rhIL-15) at escalating doses of 0.3-1.0 μg/kg for 12 consecutive days after lymphodepleting chemotherapy and haploidentical NK cells.
Number of subjects: 42
Study 31266741 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) recombinant human IL-15 (rhIL-15) at 2.0 μg/kg, given once per day for 10 days after lymphodepleting chemotherapy and haploidentical NK cells.
Number of subjects: 42
Study 31266741 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) rhIL-15
Number of subjects: 42
Study 31266741 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) rhIL-15
Number of subjects: 42
Study 31267239 — intervention group
Group type: EXPERIMENTAL
Intervention: HFdEF (LVEF < 50% at 1 year)
Number of subjects: 471
Study 31267239 — intervention group
Group type: COMPARATOR
Intervention: Persistent HFpEF (LVEF ≥ 50% both at admission and 1 year)
Number of subjects: 471
Study 31267239 — intervention group
Group type: EXPERIMENTAL
Intervention: Natriuretic peptide level > median
Number of subjects: 471
Study 31267239 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of beta-blockers, renin-angiotensin system inhibitors, and mineralocorticoid receptor antagonists
Number of subjects: 471
Study 31267365 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee extensions with elastic band
Number of subjects: 24
Study 31267365 — intervention group
Group type: EXPERIMENTAL
Intervention: One-legged squat (and sit to stand)
Number of subjects: 24
Study 31267365 — intervention group
Group type: COMPARATOR
Intervention: Strength training exercises in more simple forms (e.g. elastic bands, body weight)
Number of subjects: 24
Study 31267801 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab with ≥12 mg/week methotrexate
Number of subjects: 0
Study 31267801 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31267973 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative capecitabine
Number of subjects: 0
Study 31267973 — intervention group
Group type: EXPERIMENTAL
Intervention: Ado-trastuzumab emtansine
Number of subjects: 0
Study 31267973 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant systemic therapy
Number of subjects: 0
Study 31267980 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-based mental health intervention (1 month of support from a coach, up to 3 brief phone sessions, text messaging, and mobile mental health apps)
Number of subjects: 35
Study 31267980 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-based mental health intervention
Number of subjects: 35
Study 31268374 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunoglobulin 20%
Number of subjects: 0
Study 31268513 — intervention group
Group type: EXPERIMENTAL
Intervention: Core/lower limb muscle thickness assessment
Number of subjects: 68
Study 31268513 — intervention group
Group type: COMPARATOR
Intervention: Balance assessment using force platform system
Number of subjects: 68
Study 31268513 — intervention group
Group type: COMPARATOR
Intervention: Knee proprioception sense assessment
Number of subjects: 68
Study 31268513 — intervention group
Group type: COMPARATOR
Intervention: Muscle thickness assessment
Number of subjects: 68
Study 31269208 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (400 mg twice daily) / Etravirine (200 mg twice daily)
Number of subjects: 165
Study 31269546 — intervention group
Group type: EXPERIMENTAL
Intervention: Vosoritide 2.5 μg/kg
Number of subjects: 35
Study 31269546 — intervention group
Group type: EXPERIMENTAL
Intervention: Vosoritide 7.5 μg/kg
Number of subjects: 35
Study 31269546 — intervention group
Group type: EXPERIMENTAL
Intervention: Vosoritide 15.0 μg/kg
Number of subjects: 35
Study 31269546 — intervention group
Group type: EXPERIMENTAL
Intervention: Vosoritide 30.0 μg/kg
Number of subjects: 35
Study 31269546 — intervention group
Group type: EXPERIMENTAL
Intervention: Vosoritide (all doses)
Number of subjects: 35
Study 31269546 — intervention group
Group type: EXPERIMENTAL
Intervention: Vosoritide (up to 15.0 μg/kg)
Number of subjects: 35
Study 31269546 — intervention group
Group type: EXPERIMENTAL
Intervention: Vosoritide (15.0 and 30.0 μg/kg)
Number of subjects: 35
Study 31269854 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0